CXCL12 AND VEGF SYNERGISTICALLY INDUCE NEOANGIOGENESIS IN HUMAN OVARIAN CANCERS
CXCL12 AND VEGF SYNERGISTICALLY INDUCE NEOANGIOGENESIS IN HUMAN OVARIAN CANCERS
批准号:
7562354
负责人:
I KRYCZEK
金额:
$3.04万
依托单位国家:
美国
项目类别:
财政年份:
2007
资助国家:
美国
项目状态:
已结题
起止时间:
2007-05-01 至 2008-04-30
关键词:
ApoptosisBiological AssayCXC ChemokinesCXCL12 geneCXCR4 geneComputer Retrieval of Information on Scientific Projects DatabaseFibroblast Growth FactorFundingGrantHumanHypoxiaInstitutionLiquid substanceMalignant NeoplasmsMalignant neoplasm of ovaryMediatingOvarian CarcinomaPathologicPathway interactionsPatientsProductionResearchResearch PersonnelResourcesSerumSignal TransductionSourceStarvationTumor AngiogenesisUnited States National Institutes of HealthVascular Endothelial Cellangiogenesisantiangiogenesis therapybasecell motilityin vivomalignant ascitesmatrigelmigrationneovascularizationnoveloutcome forecastovarian neoplasmreceptortumor
中文摘要
这个子项目是许多研究子项目中利用
资源由NIH/NCRR资助的中心拨款提供。子项目和
调查员(PI)可能从NIH的另一个来源获得了主要资金,
并因此可以在其他清晰的条目中表示。列出的机构是
该中心不一定是调查人员的机构。
卵巢癌预后较差,常伴有多灶性I.P。播散伴有强烈的新生血管。为了检测肿瘤微环境中的肿瘤血管生成,我们研究了未经治疗的卵巢癌患者的恶性腹水和肿瘤。在Matrigel实验中,我们观察到恶性腹水在体内诱导了有效的新生血管。我们在恶性腹水中检测到相当数量的血管内皮细胞生长因子(VEGF)。然而,病理浓度的血管内皮生长因子不足以诱导体内血管生成。我们发现卵巢肿瘤强烈表达CXC趋化因子基质衍生因子(SDF-1/CXCL12)。高浓度的CXCL12,而不是病理浓度的CXC12,可在体内诱导血管生成。值得注意的是,病理浓度的血管内皮生长因子和CXCL12有效并协同地诱导体内血管生成。血管内皮细胞(VEC)的迁移、扩增和存活构成了血管生成的基本功能网络。我们进一步为解释CXCL12和血管内皮生长因子之间的相互作用提供了机制基础。我们发现,血管内皮生长因子上调血管内皮细胞上CXCL12、CXCR4受体的表达,并协同CXCL12介导的血管内皮细胞迁移。CXCL12协同VEGF介导的血管内皮细胞扩增,协同保护血管内皮细胞免受血清饥饿诱导的血管内皮细胞凋亡。最后,我们发现缺氧同时诱导肿瘤细胞CXCL12和血管内皮生长因子的产生。因此,低氧触发的肿瘤细胞CXCL12和血管内皮生长因子在体内形成协同的血管生成轴。低氧诱导的信号可能是启动和维持CXCL12和血管内皮生长因子介导的主动协同血管生成途径的重要因素。因此,阻断这一协作轴,而不仅仅是血管内皮生长因子,将是治疗癌症的一种新的有效的抗血管生成策略。
英文摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
Ovarian carcinomas have a poor prognosis, often associated with multifocal i.p. dissemination accompanied by intense neovascularization. To examine tumor angiogenesis in the tumor microenvironment, we studied malignant ascites and tumors of patients with untreated ovarian carcinoma. We observed that malignant ascites fluid induced potent in vivo neovascularization in Matrigel assay. We detected a sizeable amount of vascular endothelial cell growth factor (VEGF) in malignant ascites. However, pathologic concentration of VEGF is insufficient to induce in vivo angiogenesis. We show that ovarian tumors strongly express CXC chemokine stromal-derived factor (SDF-1/CXCL12). High concentration of CXCL12, but not the pathologic concentration of CXC12 induces in vivo angiogenesis. Strikingly, pathologic concentrations of VEGF and CXCL12 efficiently and synergistically induce in vivo angiogenesis. Migration, expansion, and survival of vascular endothelial cells (VEC) form the essential functional network of angiogenesis. We further provide a mechanistic basis for explaining the interaction between CXCL12 and VEGF. We show that VEGF up-regulates the receptor for CXCL12, CXCR4 expression on VECs, and synergizes CXCL12-mediated VEC migration. CXCL12 synergizes VEGF-mediated VEC expansion and synergistically protects VECs from sera starvation-induced apoptosis with VEGF. Finally, we show that hypoxia synchronously induces tumor CXCL12 and VEGF production. Therefore, hypoxia triggered tumor CXCL12 and VEGF form a synergistic angiogenic axis in vivo. Hypoxia-induced signals would be the important factor for initiating and maintaining an active synergistic angiogeneic pathway mediated by CXCL12 and VEGF. Thus, interrupting this synergistic axis, rather than VEGF alone, will be a novel efficient antiangiogenesis strategy to treat cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
B7-H4 EXPRESSION ID'S A SUPPRESSIVE MACROPHAGE POPULATION IN OVARIAN CARCINOMA
-
批准号:7562386
-
项目类别:
-
资助金额:$3.04万
-
财政年份:2007
-
负责人:I KRYCZEK
-
依托单位:
CXCL12 AND VEGF SYNERGISTICALLY INDUCE NEOANGIOGENESIS IN HUMAN OVARIAN CANCERS
-
批准号:7349120
-
项目类别:
-
资助金额:$3.1万
-
财政年份:2006
-
负责人:I KRYCZEK
-
依托单位:
海外基金